Phase 2 Colorectal Cancer Trial, Recruiting NCT06455124 Sponsor: Fudan University Condition: Colorectal Cancer
Back to Colorectal Cancer

Phase 2 Colorectal Cancer Trial, Recruiting

NCT06455124
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 75 years old, of any gender
  • People whose cancer has been confirmed by laboratory testing to be a type called adenocarcinoma
  • People whose tumour is located close to the opening of the bowel (within 7 cm)
  • People who have already had a local surgical removal of their rectal cancer and whose results show either an early-stage tumour (pT1) with at least one concerning feature — such as cancer cells at or very near the edge of the removed tissue, deeper tissue involvement, poor cell appearance under a microscope, cancer spreading into nearby small vessels or nerves, or certain tumour growth patterns — or a slightly more advanced early tumour (pT2)
  • People who have decided not to proceed with full radical surgery
  • People whose cancer has not spread to the pelvis or other parts of the body
  • People who are in a reasonable general state of health, as measured by a standard scoring system (confirm with trial site)
  • People who are willing and able to follow the trial requirements consistently
  • People whose tumour has a specific molecular characteristic known as MSS or pMMR (confirm with trial site)
  • People who have not previously received any cancer treatment or immunotherapy
  • People who have signed a consent form agreeing to take part

Who may not be able to join:

  • People who are pregnant or currently breastfeeding
  • People whose cancer has been confirmed as a specific type called signet ring cell carcinoma
  • People who have had another cancer diagnosed within the past 5 years
  • People with serious health conditions, such as severe mental health disorders, significant heart disease, or an infection that is not under control
  • People with a disease affecting the immune system, or who have been taking immune-suppressing medications long-term
  • People whose blood test results fall below certain required levels for blood cells and organ function (confirm specific values with trial site)
  • People with a condition called DPD deficiency, which affects how certain medicines are processed by the body
  • People who are known to be allergic to any component of the trial treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 021-64175590

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
8 May 2024
Est. completion
30 June 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

3y LRFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov